Hosted on MSN1h
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal
This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of ...
Delta Air Lines, Walgreens and TSMC rise premarket; Nvidia, AMD fall
Taiwan Semiconductor Manufacturing (NYSE: TSM) stock rose 1.2% after the world’s biggest contract chipmaker reported ...
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, ...
Pfizer (NYSE:PFE) Price Target Lowered to $29.00 at UBS Group
Pfizer (NYSE:PFE – Get Free Report) had its price objective lowered by analysts at UBS Group from $31.00 to $29.00 in a ...
Pfizer (NYSE:PFE) Stock Price Down 0.8% on Analyst Downgrade
Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price fell 0.8% during trading on Thursday after UBS Group lowered their price target on the stock from $31.00 to $29.00. UBS Group currently has a ...
Royalty Pharma Announces Dividend Increase
Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the ...